featured
Adjuvant Chemotherapy ± Trastuzumab in High-Risk Invasive HER2-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2
J. Clin. Oncol 2019 Dec 10;[EPub Ahead of Print], L Fehrenbacher, RS Cecchini, CE Geyer, P Rastogi, JP Costantino, JN Atkins, JP Crown, J Polikoff, JF Boileau, L Provencher, C Stokoe, TD Moore, A Robidoux, PJ Flynn, VF Borges, KS Albain, SM Swain, S Paik, EP Mamounas, N WolmarkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.